242 related articles for article (PubMed ID: 20085435)
1. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
[TBL] [Abstract][Full Text] [Related]
2. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
[TBL] [Abstract][Full Text] [Related]
3. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
5. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.
Jakubowski JA; Bourguet N; Boulay-Moine D; Sugidachi A; Yamaguchi S; Barragan P; Zhou C; Moulard M
Thromb Haemost; 2012 Feb; 107(2):388-95. PubMed ID: 22186965
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Tsantes A; Ikonomidis I; Papadakis I; Kottaridi C; Tsante A; Kalamara E; Kardoulaki A; Kopterides P; Kapsimali V; Karakitsos P; Lekakis J; Travlou A
Platelets; 2012; 23(6):481-9. PubMed ID: 22646492
[TBL] [Abstract][Full Text] [Related]
8. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
10. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
11. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
Manolopoulos P; Glenn JR; Fox SC; May JA; Dovlatova NL; Tang SW; Thomas NR; Ralevic V; Heptinstall S
Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
Aleil B; Ravanat C; Cazenave JP; Rochoux G; Heitz A; Gachet C
J Thromb Haemost; 2005 Jan; 3(1):85-92. PubMed ID: 15634270
[TBL] [Abstract][Full Text] [Related]
13. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
16. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
17. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
[TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
19. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
20. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
Frere C; Cuisset T; Quilici J; Camoin L; Carvajal J; Morange PE; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Oct; 98(4):838-43. PubMed ID: 17938809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
